CRH Medical (TSX: CRH), the Healthcare company was revisited today, and remains undervalued for at least one analyst on the street. The company received a Buy rating from TD Securities’ analyst Lennox Gibbs, with a C$5.50 price target.
According to TipRanks.com, Gibbs is ranked #4322 out of 4839 analysts.
Read also: Why Did Apricus Biosciences (APRI) Stock Shoot the Lights Out Today?
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CRH Medical with a C$5.25 average price target, implying a 18.0% upside from current levels. In a report issued on July 26, Canaccord Genuity also assigned a Buy rating to the stock with a C$5 price target.
.
Based on CRH Medical’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of C$1.81 million. In comparison, last year the company had a GAAP net loss of C$663.7K.
CRH Medical Corp. engages in the provision of gastroenterologists with innovative services and products for the treatment of gastrointestinal diseases. It offers CRH O’Regan System, which focuses on physician education, patient outcomes, and patient awareness. The company was founded in 2000 and is headquartered in Vancouver, Canada.
The company’s shares closed on Thursday at C$4.45, close to its 52-week high of C$4.76.
